| Literature DB >> 16234811 |
Marta Paterlini1, Stanislav S Zakharenko, Wen-Sung Lai, Jie Qin, Hui Zhang, Jun Mukai, Koen G C Westphal, Berend Olivier, David Sulzer, Paul Pavlidis, Steven A Siegelbaum, Maria Karayiorgou, Joseph A Gogos.
Abstract
Microdeletions of 22q11.2 represent one of the highest known genetic risk factors for schizophrenia. It is likely that more than one gene contributes to the marked risk associated with this locus. Two of the candidate risk genes encode the enzymes proline dehydrogenase (PRODH) and catechol-O-methyltransferase (COMT), which modulate the levels of a putative neuromodulator (L-proline) and the neurotransmitter dopamine, respectively. Mice that model the state of PRODH deficiency observed in humans with schizophrenia show increased neurotransmitter release at glutamatergic synapses as well as deficits in associative learning and response to psychomimetic drugs. Transcriptional profiling and pharmacological manipulations identified a transcriptional and behavioral interaction between the Prodh and Comt genes that is likely to represent a homeostatic response to enhanced dopaminergic signaling in the frontal cortex. This interaction modulates a number of schizophrenia-related phenotypes, providing a framework for understanding the high disease risk associated with this locus, the expression of the phenotype, or both.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16234811 DOI: 10.1038/nn1562
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 24.884